close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.095 +0.315 (+6.59%)
Delayed Quote Updated: 9:44 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
23 24 Next >
News headline image
Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet ↗
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit. 
Via InvestorPlace
News headline image
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday ↗
Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering. The clinical-stage biotech company also said it plans... 
Via Benzinga
News headline image
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
3 AI Stocks on the Edge of a Massive Surge ↗
Writers covering the AI stocks space agree on one thing: Nvidia’s dramatic rise is spawning a whole new wave of AI winners. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
How Is The Market Feeling About Recursion Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! 
Via InvestorPlace
News headline image
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On? ↗
After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by... 
Via Benzinga
News headline image
Recursion Announces Proposed Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening? ↗
Shares of clinical stage biotech company Recursion Pharmaceuticals Inc (NASDAQ:RXRX) are trading higher Tuesday. The company's CEO Chris Gibson joined CNBC for an interview ahead of a presentation with... 
Via Benzinga
News headline image
What's Going On With Recursion Pharmaceuticals Stock Monday? ↗
Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
News headline image
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th ↗
The global 
Via Talk Markets
News headline image
3 Stocks Under $10 Set to Quadruple by 2025: June Edition ↗
Low-priced stocks under $10 can be explosively awarding if you spot the right one at the right time with the right catalyst. 
Via InvestorPlace
News headline image
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week ↗
The global 
Via Talk Markets
News headline image
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim ↗
The CEO has set a high bar for the business, and if it hits it, the stock could easily 10x in value. 
Via The Motley Fool
News headline image
Nvidia’s Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance ↗
These Nvidia partner stocks stand to gain from the semiconductor's industry dominance, but they have plenty of upside of their own. 
Via InvestorPlace
News headline image
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider ↗
Both of these companies could soon set the standard in their fields. 
Via The Motley Fool
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Cathie Wood Owns These 2 AI Stocks. Should You? ↗
One looks like a solid option. The other one, not so much. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Recursion Pharmaceuticals Stock a Millionaire-Maker? ↗
Recursion Pharmaceuticals hopes to transform the healthcare industry with the help of AI. 
Via The Motley Fool
News headline image
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
Published open-access today in Nature Genetics, “High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies novel evidence of a proximity bias in... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk ↗
You don't need to buy her picks, but it's worth understanding them. 
Via The Motley Fool
News headline image
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.